Go to deals
Healthcare

Genedrive has successfully completed an oversubscribed US$10 million equity fundraise

May 2020 — Genedrive plc has completed an equity fundraising to support the rapid development of the Genedrive® SARS-CoV-2 assays, fund the scale-up of the Genedrive-96-SARS-CoV-2 test including build-up of inventory for an initial period, fund product development, commercialization and general corporate purposes.

Genedrive is a molecular diagnostics company developing and commercializing a low-cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company is passionate about the opportunity to not only build a sustainable business around molecular diagnostics, but to play an important role in the diagnostic and treatment challenges presented by global health issues.

Our role in the transaction

Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Genedrive plc on its oversubscribed equity fundraising.

Talk to the deal team

Geoff Nash

Director
London, United Kingdom
Oaklins Cavendish

Related deals

Life & Mobility has attracted investor Bolster Investment Partners
Private Equity | Healthcare

Life & Mobility has attracted investor Bolster Investment Partners

Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.  

Learn more
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Private Equity | Healthcare

Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors

Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.

Learn more
Asana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Healthcare

Asana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital

Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.

Learn more